BEST UNLIMITED TURBO LONG CERTIFICATE - ELI LILLY & CO | Real-time Borsa Italiana 11:34:07 2024-07-16 am EDT | ||
| 14.3 EUR | -1.72% |
|
| Current month | +32.88% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-07-16 | 14.3 | -1.72% |
| 24-07-15 | 14.55 | +1.18% |
| 24-07-12 | 14.38 | +8.94% |
| 24-07-11 | 13.2 | -2.00% |
| 24-07-10 | 13.47 | +3.06% |
Real-time Borsa Italiana
Last update July 16, 2024 at 11:34 am EDT
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Société Générale
|
| S36546 | |
| ISIN | DE000SY1RW33 |
| Date issued | 2024-06-18 |
| Strike | 797.9 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | - € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 15.89 € |
|---|---|
| Lowest since issue | 8.02 € |
| Spread | 0.12 € |
| Spread % | 0.80% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
950.5
USD
Average target price
893.1
USD
Spread / Average Target
-6.04%
- Stock Market
- Certificates
- S36546 Certificat
